3
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Lipid-Polymer Hybrid Nanoparticles for Controlled Delivery of Hydrophilic and Lipophilic Doxorubicin for Breast Cancer Therapy [Erratum]

      International Journal of Nanomedicine

      Dove

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tahir N, Madni A, Correia A, et al. Int J Nanomed. 2019;14:4961–4974. On page 4967, Figure 3 artwork is incorrect, Figure 4 artwork was mistakenly added by the Editorial staff during the publication process. The correct figure is: Following feedback from a reader, we found the incorrect artwork was presented for Figure 3. Figure 3 FTIR spectra of PLGA (A), lecithin (B), DSPE-PEG 2000 (C), Luterol (D), DOX (E) blank formulation (F), and DOX loaded LPHNPS (G). Abbreviations: DOX, doxorubicin; DSPE-PEG 2000, 1,2-distearoyl-Sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)]-2000; LPHNPs, lipid polymer hybrid nanoparticles; PLGA, poly (D, L-lactide-co-glicolide).

          Related collections

          Author and article information

          Journal
          Int J Nanomedicine
          Int J Nanomedicine
          IJN
          intjnano
          International Journal of Nanomedicine
          Dove
          1176-9114
          1178-2013
          05 February 2020
          2020
          05 February 2020
          : 15
          : 839
          Article
          247761
          10.2147/IJN.S247761
          7008583
          © 2020 Tahir et al.

          This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

          Page count
          Pages: 1
          Categories
          Erratum

          Molecular medicine

          Comments

          Comment on this article